Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

3(50.0%)

Phase 2

1(16.7%)

N/A

1(16.7%)

Phase 1

1(16.7%)

6Total

Phase 4(3)

Phase 2(1)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01972763Phase 1Completed

Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

Role: lead

NCT02297204Phase 4Completed

The Endurance 1 Trial

Role: lead

NCT01870427Phase 4Completed

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

Role: lead

NCT02001701Not ApplicableWithdrawn

Intravitreal Gas for Vitreomacular Adhesion

Role: lead

NCT01870440Phase 4Completed

TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema

Role: lead

NCT01284478Phase 2Completed

Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

Role: lead

All 6 trials loaded